BMO Maintains Outperform on Pfizer (PFE) March 2026

BMO Capital maintained an Outperform rating on Pfizer Inc. (PFE) on March 9, 2026. The move is the only recent change in coverage and reflects BMO’s view after Phase 2 data, according to StreetInsider. The phrase PFE analyst rating guides this update and frames what investors should expect in near term. BMO left the rating unchanged and reported a modest market reaction of 0.77% ($0.20). We cover what the BMO action means for shareholders and how this fits into broader analyst coverage of Pfizer

PFE analyst rating: BMO maintains Outperform

On March 9, 2026 BMO Capital reiterated an Outperform rating on Pfizer Inc. (PFE) after Phase 2 results, per StreetInsider source. The firm did not publish a new price target in the note, so the action is a reaffirmation rather than an upgrade or downgrade.

Analyst action and specifics on price targets

BMO’s note kept the rating but did not list a new PFE price target, leaving the target effectively unchanged in published coverage. StreetInsider records BMO’s action as a reiteration after clinical data, which signals confidence in Pfizer’s development pipeline without pushing valuation expectations higher.

What the BMO move means for investors and trading

A maintained Outperform means BMO expects Pfizer to outperform peers, but it is not a fresh buy signal. Investors should view the PFE analyst rating reiteration as cautious support and look for future catalysts or updated targets before increasing position sizes.

Stock reaction and market context

Pfizer’s immediate market response was small, with a 0.77% ($0.20) move reported at the time of the note. Pfizer’s market capitalization stands at $152,448,828,485, and the muted price move suggests markets had largely priced in the Phase 2 outcome.

Historical analyst coverage and trend

Pfizer has long attracted broad analyst coverage across major banks and independent research shops, with mixed ratings historically. Reiterated Outperform calls like BMO’s fit a pattern of steady support for Pfizer’s commercial franchises and pipeline while analysts wait for clearer late‑stage data or guidance changes.

Meyka grade and platform insight

Meyka AI rates PFE with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka’s real‑time tracking flags a maintained Outperform as supportive but not transformative for the grade.

Final Thoughts

BMO Capital’s action on March 9, 2026 was a reaffirmation, not an upgrade or downgrade, and it keeps the firm’s stance at Outperform for Pfizer Inc. (PFE). The PFE analyst rating reiteration follows Phase 2 data and did not include a new price target, which leaves valuation guidance unchanged in the near term. Market response was modest at 0.77% ($0.20), reflecting expectations that the clinical update would confirm, not surprise. For investors, the BMO note signals continued confidence in Pfizer’s pipeline and commercial base, but it is not an immediate catalyst to add positions without a clear target revision or fresh data. Remember that Meyka AI rates PFE with a grade of B+, a composite view that includes relative index performance, sector dynamics, financial growth, key ratios, and analyst sentiment. These grades are not guarantees and we are not financial advisors. Use the reaffirmation as part of a broader review of risk, timelines, and income needs, and consult your advisor before trading

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.